Stocks Health care PYXS
NASDAQ · Health carePyxis Oncology, Inc. (PYXS)
It posted a net loss of $86.7M. In fiscal 2025 capital spending exceeded operating cash flow by $63.5M. At September 30, 2026 it held $3.9M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Pyxis Oncology, Inc.
- Net worth
- Pyxis Oncology, Inc. has a market value (market cap) of $133.5M at the latest share price, and shareholders' equity of $41.3M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $13.9M (-14.2% year on year), with a net loss of $79.6M.
- Cash flow
- In fiscal 2025 operations used $63.5M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Pyxis Oncology, Inc.'s next report is expected around March 22, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Pyxis Oncology, Inc. does
Pyxis Oncology, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker PYXS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $13.9M | -$79.6M | -$1.28 | -$63.5M |
| 2024 | $16.1M | -$77.3M | -$1.32 | -$57.9M |
| 2023 | n/a | -$73.8M | -$1.85 | -$77.4M |
| 2022 | n/a | -$120.7M | -$3.65 | -$95.7M |
| 2021 | n/a | -$76M | -$8.95 | -$35.9M |
| 2021 | n/a | -$12.8M | -$12.45 | -$11.6M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where PYXS ranks in Health care
Latest SEC filings
What Pyxis Oncology, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026
- November 5, 2026
- November 3, 2026Passive stake changed SCHEDULE 13G/A
- October 21, 2026Proxy statement DEF 14A
- October 9, 2026Preliminary proxy statement PRE 14A
- October 9, 2026Passive stake changed SCHEDULE 13G/A
- October 5, 2026Passive stake (5% or more) SCHEDULE 13G
- October 2, 2026Passive stake changed SCHEDULE 13G/A
- October 1, 2026Material agreement8-KPyxis Oncology closed an underwritten public offering raising approximately $102.8 million in net proceeds.
- September 9, 2026
Insider trades
What the people running Pyxis Oncology, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| June 30, 2026 | Dupont JakobDirector | Exercised options | 35,000 | $56K |
| June 30, 2026 | Dupont JakobDirector | Soldpre-planned (10b5-1) | 35,000 | $107.1K |
| March 24, 2026 | Wadhane JitendraPrin Fin & Acct Officer | Received as pay | 109,461 | - |
Who owns PYXS
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| GordonMD Global Investments LP13G, passive with 3 related filers | 16.4% | October 9, 2026 |
| Lara Sullivan, M.D.13D, may seek influence | 11.21% | April 2, 2025 |
| Bvf Partners L P13G, passive with 9 related filers | 9.99% | July 10, 2026 |
| Laurion Capital Management LP13G, passive with 2 related filers | 7.72% | February 9, 2026 |
| Coastlands Capital LP13G, passive with 4 related filers | 5.42% | October 5, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 76 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| GordonMD Global Investments LP | 10,024,909 | +5,903,039 |
| Pfizer Inc | 7,032,770 | 0 |
| Laurion Capital Management LP | 4,900,888 | -96,445 |
| Vanguard Capital Management LLC | 2,075,997 | +42,487 |
| Atle Fund Management AB | 966,459 | +769,423 |
| BlackRock, Inc. | 867,934 | +79,095 |
| Palo Alto Investors LP | 864,277 | -146,233 |
| Marshall Wace, Llp | 830,544 | +476,127 |
| Renaissance Technologies LLC | 772,232 | -116,448 |
| Geode Capital Management, LLC | 591,849 | -6,272 |
| Woodline Partners LP | 523,999 | new |
| 683 Capital Management, LLC | 459,367 | -436,896 |
| Jacobs Levy Equity Management, Inc | 428,606 | -32,391 |
| Longaeva Partners L.P. | 353,582 | -149,632 |
| Decheng Capital LLC | 326,810 | 0 |
| Vanguard Fiduciary Trust Co | 302,986 | +2,089 |
| Jane Street Group, LLC | 290,090 | -14,369 |
| State Street Corp | 248,837 | 0 |
| Millennium Management LLC | 233,004 | -164,621 |
| UBS Group AG | 155,217 | -98,907 |
Insiders
3 insiders reported holding 632,932 shares in total, about $1M at the last price.
| Holder | Shares |
|---|---|
| Wadhane JitendraPrin Fin & Acct Officer | 512,882 |
| Humphrey RachelDirector | 81,309 |
| Dupont JakobDirector | 38,741 |
Questions about PYXS
What does Pyxis Oncology, Inc. do?
Pyxis Oncology, Inc. is a company in the Health care sector, listed on NASDAQ as PYXS. Its shares trade on NASDAQ under the ticker PYXS.
What is Pyxis Oncology, Inc.'s net worth?
Pyxis Oncology, Inc. has a market value (market cap) of $133.5M at the latest share price, and shareholders' equity of $41.3M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Pyxis Oncology, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $86.7M.
When did Pyxis Oncology, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the insider trade from November 6, 2026.
When is Pyxis Oncology, Inc.'s next earnings report?
Pyxis Oncology, Inc.'s next report is expected around March 22, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare PYXS with
Follow PYXS
Get an email when Pyxis Oncology, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Pyxis Oncology, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.